Details of Disease

General Information of Disease (ID: DISVEUR6)

Disease Name	Follicular lymphoma
Synonyms	lymphoma, follicular; follicular non-Hodgkin lymphoma; lymphoma, follicular centre cell; follicle centre lymphoma; follicular non-Hodgkin's lymphoma; follicular center cell lymphoma; lymphoma, follicular center cell; follicular centre cell lymphoma; lymphoma, follicular, malignant; follicle center lymphoma
Disease Class	2A80: Follicular lymphoma
Definition	Follicular lymphoma is a form of non-Hodgkin lymphoma characterized by a proliferation of B cells whose nodular structure of follicular architecture is preserved.
Disease Hierarchy	DISPW4EO: Indolent B-cell non-Hodgkin lymphoma DISKAXO0: Neoplasm of mature B-cells DISVEUR6: Follicular lymphoma
ICD Code	ICD-11 ICD-11: 2A80 ICD-9 ICD-9: 202 Expand ICD-11 '2A80 Expand ICD-10 'C82; 'C82.5; 'C82.7; 'C82.9 Expand ICD-9 202
Disease Identifiers	MONDO ID MONDO_0018906 MESH ID D008224 UMLS CUI C0024301 MedGen ID 7417 HPO ID HP:0033125 Orphanet ID 545 SNOMED CT ID 269476000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 26 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[1]
Axicabtagene ciloleucel	DMYHN59	Approved	CAR T Cell Therapy	[1]
BAY 80-6946	DMLOS5R	Approved	Small molecular drug	[2]
Betamethasone	DMAHJEF	Approved	Small molecular drug	[3]
Bleomycin	DMNER5S	Approved	Small molecular drug	[4]
Chlorambucil	DMRKE63	Approved	Small molecular drug	[5]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[6]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[7]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[8]
Glofitamab	DM45HT6	Approved	Antibody	[9]
Ibrutinib	DMHZCPO	Approved	Small molecular drug	[1]
Idelalisib	DM602WT	Approved	Small molecular drug	[10]
IPI-145	DMWA24P	Approved	Small molecular drug	[11]
Lisocabtagene maraleucel	DMP45ME	Approved	CAR T Cell Therapy	[12]
Loncastuximab tesirine	DMXSVGI	Approved	Antibody drug conjugate	[13]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[14]
Mosunetuzumab	DM15ZIB	Approved	Antibody	[15]
Nivolumab	DMAB9QE	Approved	Monoclonal antibody	[1]
Polatuzumab vedotin	DMF6Y0L	Approved	Antibody	[1]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[16]
Prednisone	DM2HG4X	Approved	Small molecular drug	[17]
Tazemetostat	DMWP1BH	Approved	Small molecular drug	[18]
Tisagenlecleucel	DMM9BJD	Approved	CAR T Cell Therapy	[1]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[19]
Umbralisib	DMYRBO1	Approved	NA	[20]
Vincristine	DMINOX3	Approved	Small molecular drug	[21]
------------------------------------------------------------------------------------


⏷ Show the Full List of 26 Drug(s)

This Disease is Treated as An Indication in 31 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
B-cell lymphoma vaccine	DMBRFUQ	Preregistration	Vaccine	[22]
Abexinostat	DM91LGU	Phase 3	Small molecular drug	[1]
BI-695500	DMT0NTL	Phase 3	NA	[23]
GP2013	DMZB45J	Phase 3	NA	[24]
MK-8808	DMT8IAJ	Phase 3	NA	[25]
PF-05280586	DMNZOCK	Phase 3	NA	[23]
Pixantrone	DMQGR45	Phase 3	Small molecular drug	[26]
SAIT101	DMI1R5S	Phase 3	Antibody	[27]
BGB-3112	DMQCFSM	Phase 2	NA	[1]
CART-19	DMHQKN6	Phase 2	CAR T Cell Therapy	[28]
INCB50465	DMZJP2T	Phase 2	NA	[1]
ME-401	DMK0UOY	Phase 2	Small molecular drug	[30]
Parsaclisib	DMYBIFS	Phase 2	Small molecular drug	[31]
Anti-CD19 CAR-T cells	DMDRYZK	Phase 1/2	CAR T Cell Therapy	[32]
Anti-CD19-CAR vector-transduced T cells	DMQXU4C	Phase 1/2	CAR T Cell Therapy	[33]
Anti-CD19/22-CAR vector-transduced T cells	DMMUSHR	Phase 1/2	CAR T Cell Therapy	[34]
Anti-CD20-CAR vector-transduced autologous T cells	DMCDUJY	Phase 1/2	CAR T Cell Therapy	[35]
CD19.CAR T Cells	DM79GPF	Phase 1/2	CAR T Cell Therapy	[36]
CD19.CAR-T cells	DMNZ7F2	Phase 1/2	CAR T Cell Therapy	[37]
CD20-Specific CAR T Cells	DMHPZ8G	Phase 1/2	CAR T Cell Therapy	[38]
GEN3013	DMZABYH	Phase 1/2	Antibody	[39]
JCAR017	DMJV2IF	Phase 1/2	CAR T Cell Therapy	[40]
JCARH125	DM8P7FC	Phase 1/2	CAR T Cell Therapy	[41]
PCAR-019	DM9DR13	Phase 1/2	CAR T Cell Therapy	[42]
AMG 562	DMQ0N5Z	Phase 1	Antibody	[43]
BCL201	DMZ51EX	Phase 1	NA	[1]
Human CD19 targeted T Cells	DM0W275	Phase 1	CAR T Cell Therapy	[44]
Oncoquest-L	DMOZ2L6	Phase 1	NA	[1]
PF-06821497	DML3WT6	Phase 1	Small molecular drug	[45]
Retroviral vector-transduced autologous T cells to express CD22-specific CARs	DMZ8WAQ	Phase 1	CAR T Cell Therapy	[46]
Anti-CD19/20-CAR vector-transduced T cells	DM3M9OY	Clinical trial	CAR T Cell Therapy	[47]
------------------------------------------------------------------------------------


⏷ Show the Full List of 31 Drug(s)

This Disease is Treated as An Indication in 1 Drugs in Phase 2 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Duvelisib	DM7USVA	Phase 2 Trial	Small molecular drug	[29]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 70 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CBX7	TTBN3HC	Limited	Genetic Variation	[49]
CCND3	TT1JXNR	Limited	Biomarker	[50]
CHIT1	TTDYX6T	Limited	Altered Expression	[51]
FCGR2B	TT5RWKQ	Limited	Biomarker	[52]
GADD45B	TTMDW9L	Limited	Biomarker	[53]
HLA-DRB1	TTUXSTW	Limited	Genetic Variation	[54]
KIR2DS1	TTVWAGF	Limited	Genetic Variation	[55]
KIR3DL2	TTQH3N0	Limited	Genetic Variation	[55]
LAIR1	TTSI7A8	Limited	Genetic Variation	[56]
NPR2	TTNB7IF	Limited	Biomarker	[57]
NRG4	TTWAGKJ	Limited	Altered Expression	[58]
P2RY8	TT84EWY	Limited	Altered Expression	[59]
PRKCE	TT57MT2	Limited	Altered Expression	[60]
PRSS1	TT2WR1T	Limited	Genetic Variation	[61]
STMN1	TT7W5OT	Limited	Biomarker	[62]
TNFRSF8	TT2GM5R	Limited	Biomarker	[63]
E2F2	TT5FYX0	Disputed	Biomarker	[64]
IL21R	TTZO9B0	Disputed	Altered Expression	[65]
IL31RA	TT9HPX0	Disputed	Altered Expression	[66]
SIRPA	TTBRJS9	Disputed	Biomarker	[67]
ZAP70	TTUMHT8	Disputed	Biomarker	[68]
BTLA	TTER58P	moderate	Altered Expression	[69]
CD46	TTMS7DF	moderate	Genetic Variation	[70]
IFNGR2	TT13TL0	moderate	Genetic Variation	[71]
MTHFR	TTQWOU1	moderate	Genetic Variation	[72]
MTR	TTUTO39	moderate	Genetic Variation	[73]
PTPRJ	TTWMKXP	moderate	Biomarker	[74]
TYMS	TTP1UKZ	moderate	Genetic Variation	[73]
ABL2	TT1A6HL	Strong	Altered Expression	[75]
ATP6AP1	TTWDM4U	Strong	Biomarker	[76]
BTK	TTGM6VW	Strong	Altered Expression	[77]
CD27	TTDO1MV	Strong	Altered Expression	[78]
CD37	TTFCW29	Strong	Biomarker	[79]
CD40	TT1ERKL	Strong	Biomarker	[80]
CDK3	TTMYWL7	Strong	Biomarker	[81]
CGB3	TTUH273	Strong	Altered Expression	[82]
CNP	TT71P0H	Strong	Genetic Variation	[83]
CREBBP	TTFRCTK	Strong	Genetic Variation	[84]
DCK	TTJOCE4	Strong	Genetic Variation	[85]
EML4	TT92GY4	Strong	Genetic Variation	[86]
EPHA7	TTAHTVG	Strong	Genetic Variation	[87]
EZH2	TT9MZCQ	Strong	Altered Expression	[88]
GBA	TT1B5PU	Strong	Biomarker	[57]
IFNA2	TTSIUJ9	Strong	Therapeutic	[89]
IL31	TT1RJXK	Strong	Altered Expression	[90]
LMO2	TTFX379	Strong	Biomarker	[81]
MALT1	TTCI81G	Strong	Biomarker	[91]
MASP2	TTR01E9	Strong	Genetic Variation	[92]
MYD88	TTB6Q2O	Strong	Genetic Variation	[93]
NSD1	TTTSJ3H	Strong	Biomarker	[94]
PAX5	TTA4REJ	Strong	Biomarker	[95]
PDCD1LG2	TTW14O3	Strong	Biomarker	[96]
REL	TT1ZCTH	Strong	Biomarker	[97]
RXRB	TTKLV96	Strong	Genetic Variation	[98]
SOX5	TTXHSZK	Strong	Biomarker	[99]
SPN	TTOZAX0	Strong	Altered Expression	[57]
TCL1A	TTUKRDV	Strong	Altered Expression	[100]
TNFAIP3	TT5W0IO	Strong	Genetic Variation	[101]
TNFRSF14	TTWGTC1	Strong	Genetic Variation	[102]
TNFRSF25	TTDV6BQ	Strong	Altered Expression	[103]
TSPO	TTPTXIN	Strong	Genetic Variation	[104]
WWP2	TT6TU05	Strong	Altered Expression	[82]
BCL2L2	TTQ79W8	Definitive	Altered Expression	[105]
CR2	TT0HUN7	Definitive	Altered Expression	[106]
CXCR5	TTIW59R	Definitive	Biomarker	[107]
FCER2	TTCH6MU	Definitive	Altered Expression	[106]
IL21	TT9QEJ6	Definitive	Biomarker	[84]
IL4R	TTDWHC3	Definitive	Genetic Variation	[108]
MKI67	TTB4UNG	Definitive	Genetic Variation	[109]
MS4A1	TTUE541	Definitive	Biomarker	[110]
------------------------------------------------------------------------------------


⏷ Show the Full List of 70 DTT(s)

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC16A10	DTPAQJO	Limited	Biomarker	[111]
SLC7A7	DTE4HJ8	Limited	Biomarker	[112]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1C4	DEAJN47	Limited	Genetic Variation	[113]
------------------------------------------------------------------------------------

This Disease Is Related to 88 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AFF3	OTR0705Z	Limited	Genetic Variation	[114]
AMPH	OTWPGWZX	Limited	Biomarker	[115]
BCL2L11	OTNQQWFJ	Limited	Genetic Variation	[116]
BCL3	OT1M5B95	Limited	Genetic Variation	[117]
C1QA	OT6XKVVA	Limited	Genetic Variation	[118]
CDK10	OTKP7TTR	Limited	Altered Expression	[119]
CDR2	OTD3ZJST	Limited	Genetic Variation	[120]
CFHR1	OT72R16T	Limited	Biomarker	[121]
CFHR5	OT7BMOYE	Limited	Biomarker	[121]
CLEC4D	OTT7X1UC	Limited	Genetic Variation	[122]
CLSTN3	OTPUFK4C	Limited	Genetic Variation	[123]
DNTT	OTFSEF12	Limited	Biomarker	[124]
DROSHA	OTCE68KZ	Limited	Altered Expression	[60]
EDIL3	OTDVVNS0	Limited	Genetic Variation	[125]
HLA-DQB1	OTVVI3UI	Limited	Genetic Variation	[126]
LMNB1	OT100T3P	Limited	Altered Expression	[127]
MIB1	OT5C404P	Limited	Genetic Variation	[109]
MNDA	OTCTKR47	Limited	Biomarker	[128]
MYOZ3	OTRN16R4	Limited	Genetic Variation	[123]
PMCH	OT3D9SA4	Limited	Altered Expression	[129]
POU2F2	OTPV0J0C	Limited	Genetic Variation	[130]
RANBP2	OTFG5CVF	Limited	Genetic Variation	[61]
RHOF	OTPA3F8Q	Limited	Altered Expression	[131]
SLC26A8	OTNCW8RJ	Limited	Biomarker	[111]
TIA1	OTGPN3P8	Limited	Biomarker	[132]
CD244	OTSMR85N	Disputed	Altered Expression	[133]
CFHR3	OTYL8SDO	Disputed	Biomarker	[134]
DDIT3	OTI8YKKE	Disputed	Biomarker	[135]
GNA13	OTVDL515	Disputed	Altered Expression	[136]
KLHL6	OTLDECOX	Disputed	Biomarker	[137]
LCP2	OT57KE22	Disputed	Biomarker	[133]
PCDHGA3	OTTOGYJA	Disputed	Biomarker	[138]
PLSCR4	OT2AMYLY	Disputed	Biomarker	[139]
RAD23B	OT0PGOG3	Disputed	Genetic Variation	[140]
RHOH	OT1J9SEB	Disputed	Biomarker	[141]
TRRAP	OT68OI2Y	Disputed	Biomarker	[139]
ETV3	OTEN03BM	moderate	Genetic Variation	[142]
KDSR	OTCIES3H	moderate	Biomarker	[143]
NAIP	OTLA925F	moderate	Biomarker	[144]
RRAGC	OTV3XCV8	moderate	Biomarker	[76]
SERPINA9	OT0OIZH1	moderate	Altered Expression	[145]
ATP6V1B2	OTNX2V4Z	Strong	Genetic Variation	[146]
BCL2L10	OTYXQJ3I	Strong	Biomarker	[147]
BCR	OTCN76C1	Strong	Biomarker	[148]
BIK	OTTH1T3D	Strong	Genetic Variation	[149]
CARD11	OTRCTLYC	Strong	Biomarker	[150]
CHGB	OT7SAQT2	Strong	Altered Expression	[82]
CROCC	OTVNOZSM	Strong	Biomarker	[151]
DAP	OT5YLL7E	Strong	Biomarker	[152]
DEFB126	OT9NHGQE	Strong	Genetic Variation	[92]
DOCK2	OTZTS3PA	Strong	Biomarker	[153]
EBF1	OTZ61YYH	Strong	Biomarker	[154]
FBP1	OTQBANEP	Strong	Altered Expression	[155]
GPANK1	OT1TN2KT	Strong	Genetic Variation	[98]
GRAMD1B	OTCG1GX2	Strong	Genetic Variation	[156]
HLA-DPB1	OTW8JHU2	Strong	Genetic Variation	[157]
HVCN1	OT4ALYU4	Strong	Biomarker	[158]
KMT2B	OTMMAZQX	Strong	Genetic Variation	[159]
KMT2D	OTTVHCLY	Strong	Genetic Variation	[160]
MARCHF8	OTH7PNN2	Strong	Altered Expression	[161]
MDN1	OTNBSPTW	Strong	Genetic Variation	[162]
MEF2B	OT880SE6	Strong	Biomarker	[163]
MLXIP	OT30UNI7	Strong	Altered Expression	[161]
MRPL28	OT4LUTZU	Strong	Posttranslational Modification	[164]
MYLIP	OTL0PFGV	Strong	Altered Expression	[161]
MZB1	OT071TET	Strong	Altered Expression	[165]
NAPSA	OT6F8IAL	Strong	Altered Expression	[166]
NKX6-3	OTAMUC7H	Strong	Altered Expression	[167]
NXT1	OT0VO6AY	Strong	Posttranslational Modification	[164]
PATZ1	OT0X9WGR	Strong	Altered Expression	[168]
POU2AF1	OTOO6WHL	Strong	Altered Expression	[169]
PSMB1	OTYRFBAH	Strong	Genetic Variation	[170]
RBM45	OTWTHD77	Strong	Genetic Variation	[54]
RERE	OT3G4GBZ	Strong	Altered Expression	[75]
RING1	OTCWTAX0	Strong	Genetic Variation	[98]
RPS20	OTI8052R	Strong	Genetic Variation	[171]
RTEL1	OTI3PJCT	Strong	Altered Expression	[172]
SLC7A4	OTAVC6QS	Strong	Altered Expression	[173]
SPART	OTIVOS2I	Strong	Posttranslational Modification	[174]
SRSF3	OTOFT707	Strong	Genetic Variation	[175]
TCL1B	OT4CSO39	Strong	Altered Expression	[100]
TMEM54	OTPQEFR0	Strong	Altered Expression	[176]
ARID1A	OTRWDV3P	Definitive	Genetic Variation	[94]
DAPK1	OTNCNUCO	Definitive	Posttranslational Modification	[174]
GCSAM	OTZNOPYK	Definitive	Biomarker	[177]
KRT20	OT4RB40L	Definitive	Biomarker	[110]
NFKBIE	OTLAYEL9	Definitive	Genetic Variation	[178]
PRIMA1	OT9ITT3P	Definitive	Biomarker	[179]
------------------------------------------------------------------------------------


⏷ Show the Full List of 88 DOT(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3	Betamethasone FDA Label
4	Bleomycin FDA Label
5	Chlorambucil FDA Label
6	Cortisone acetate FDA Label
7	Dexamethasone FDA Label
8	Doxorubicin FDA Label
9	ClinicalTrials.gov (NCT04246086) A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, Glofitamab + Lenalidomide, and Glofitamab + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma. U.S. National Institutes of Health.
10	Idelalisib FDA Label
11	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
12	ClinicalTrials.gov (NCT03484702) Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
13	ClinicalTrials.gov (NCT04699461) Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS 6). U.S. National Institutes of Health.
14	Methylprednisolone FDA Label
15	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761263.
16	Prednisolone FDA Label
17	Prednisone FDA Label
18	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
19	Triamcinolone FDA Label
20	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
21	Vincristine FDA Label
22	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006688)
23	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
24	ClinicalTrials.gov (NCT01419665) GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) (ASSIST_FL). U.S. National Institutes of Health.
25	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034367)
26	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7544).
27	ClinicalTrials.gov (NCT02809053) A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma (RAMO-2). U.S. National Institutes of Health.
28	ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
29	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 211155
30	ClinicalTrials.gov (NCT03768505) Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL). U.S. National Institutes of Health.
31	ClinicalTrials.gov (NCT04434937) Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213). U.S. National Institutes of Health.
32	ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
33	ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
34	ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
35	ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
36	ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
37	ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
38	ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
39	ClinicalTrials.gov (NCT03625037) GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.
40	ClinicalTrials.gov (NCT02631044) Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
41	ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
42	ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
43	ClinicalTrials.gov (NCT03571828) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma. U.S. National Institutes of Health.
44	ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
45	ClinicalTrials.gov (NCT03460977) PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma. U.S. National Institutes of Health.
46	ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
47	ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
48	J Clin Oncol 27:15s, 2009 (suppl, abstr 8566).
49	Role of the chromobox protein CBX7 in lymphomagenesis.Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5389-94. doi: 10.1073/pnas.0608721104. Epub 2007 Mar 20.
50	Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma.Hum Pathol. 2011 Jul;42(7):972-82. doi: 10.1016/j.humpath.2010.10.011. Epub 2011 Feb 2.
51	Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets.Blood. 2012 Jan 19;119(3):e9-e21. doi: 10.1182/blood-2011-02-339556. Epub 2011 Nov 22.
52	Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas.Oncogene. 2001 Nov 15;20(52):7686-93. doi: 10.1038/sj.onc.1204989.
53	Inherited genetic variation and overall survival following follicular lymphoma.Am J Hematol. 2012 Jul;87(7):724-6. doi: 10.1002/ajh.23184. Epub 2012 Mar 31.
54	The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.Leuk Lymphoma. 2019 Dec;60(12):2899-2908. doi: 10.1080/10428194.2019.1617858. Epub 2019 Jun 19.
55	Natural Killer Cell Immunoglobulin-like Receptor (KIR) genotypes in Follicular Lymphoma patients: results of a pilot study.Gene. 2013 Aug 1;525(1):136-40. doi: 10.1016/j.gene.2013.03.144. Epub 2013 May 1.
56	Clonal evolution of a follicular lymphoma: evidence for antigen selection.Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6770-4. doi: 10.1073/pnas.89.15.6770.
57	The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.Cytometry B Clin Cytom. 2018 May;94(3):451-458. doi: 10.1002/cyto.b.21533. Epub 2017 May 24.
58	The role of neuregulin4 and HER4 in gastrointestinal malignant lymphoma.Mol Med Rep. 2011 Nov-Dec;4(6):1151-5. doi: 10.3892/mmr.2011.542. Epub 2011 Jul 26.
59	Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphoma.Leukemia. 2007 Oct;21(10):2221-5. doi: 10.1038/sj.leu.2404784. Epub 2007 Jun 7.
60	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response.Haematologica. 2012 Apr;97(4):586-94. doi: 10.3324/haematol.2011.048132. Epub 2011 Nov 18.
61	A tandem triplication, trp(1)(q21q32), in a patient with follicular lymphoma: a case study and review of the literature.Cancer Genet Cytogenet. 2009 Mar;189(2):127-31. doi: 10.1016/j.cancergencyto.2008.11.005.
62	Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma.Oncotarget. 2017 May 29;8(37):61425-61439. doi: 10.18632/oncotarget.18251. eCollection 2017 Sep 22.
63	Extra copies of chromosome 2 are a recurring aberration in ALK-negative lymphomas with anaplastic morphology.Mod Pathol. 2005 Feb;18(2):235-43. doi: 10.1038/modpathol.3800299.
64	miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.Hum Pathol. 2016 Apr;50:118-26. doi: 10.1016/j.humpath.2015.11.011. Epub 2015 Nov 30.
65	Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease.Leuk Lymphoma. 2013 Jun;54(6):1212-20. doi: 10.3109/10428194.2012.742522. Epub 2012 Nov 23.
66	The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma.Leukemia. 2015 Apr;29(4):958-67. doi: 10.1038/leu.2014.291. Epub 2014 Oct 6.
67	SIRP expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma.Blood Cancer J. 2019 Oct 14;9(10):84. doi: 10.1038/s41408-019-0246-0.
68	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.J Pathol. 2005 Mar;205(4):507-13. doi: 10.1002/path.1727.
69	High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.Am J Clin Pathol. 2009 Oct;132(4):589-96. doi: 10.1309/AJCPPHKGYYGGL39C.
70	A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival.BMC Med Genet. 2014 Oct 8;15:113. doi: 10.1186/s12881-014-0113-6.
71	Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma.Blood. 2011 Jan 13;117(2):585-90. doi: 10.1182/blood-2010-07-295097. Epub 2010 Oct 15.
72	Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of follicular lymphoma: a meta-analysis.Tumour Biol. 2013 Jun;34(3):1467-71. doi: 10.1007/s13277-013-0670-x. Epub 2013 Jan 29.
73	Implication of the folate-methionine metabolism pathways in susceptibility to follicular lymphomas.Blood. 2006 Jul 1;108(1):278-85. doi: 10.1182/blood-2005-04-1567. Epub 2006 Jan 12.
74	CD148 and CD27 are expressed in B cell lymphomas derived from both memory and nave B cells.Leuk Lymphoma. 2002 Sep;43(9):1855-8. doi: 10.1080/1042819021000006385.
75	Evaluation of ARG protein expression in mature B cell lymphomas compared to non-neoplastic reactive lymph node.Cell Immunol. 2009;259(2):111-6. doi: 10.1016/j.cellimm.2009.06.004. Epub 2009 Jun 6.
76	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.Nat Genet. 2016 Feb;48(2):183-8. doi: 10.1038/ng.3473. Epub 2015 Dec 21.
77	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.Blood. 2018 Jan 11;131(2):182-190. doi: 10.1182/blood-2017-09-804641. Epub 2017 Oct 26.
78	Mass Cytometry Analysis Reveals that Specific Intratumoral CD4(+) T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma.Cell Rep. 2019 Feb 19;26(8):2178-2193.e3. doi: 10.1016/j.celrep.2019.01.085.
79	The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.Front Oncol. 2019 Nov 29;9:1301. doi: 10.3389/fonc.2019.01301. eCollection 2019.
80	RIP1 has a role in CD40-mediated apoptosis in human follicular lymphoma cells.Immunobiology. 2017 Nov;222(11):998-1003. doi: 10.1016/j.imbio.2017.06.001. Epub 2017 Jun 10.
81	Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling.BMC Med Genomics. 2011 Mar 31;4:27. doi: 10.1186/1755-8794-4-27.
82	Dysregulated expressions of PTEN, NF-B, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia.Am J Transl Res. 2019 Feb 15;11(2):1092-1101. eCollection 2019.
83	Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma.Mol Cancer Res. 2019 Feb;17(2):567-582. doi: 10.1158/1541-7786.MCR-18-0582. Epub 2018 Oct 24.
84	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.Clin Cancer Res. 2019 Jan 15;25(2):735-746. doi: 10.1158/1078-0432.CCR-18-1153. Epub 2018 Oct 22.
85	Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.Leuk Res. 2011 Apr;35(4):431-7. doi: 10.1016/j.leukres.2010.09.026. Epub 2010 Oct 27.
86	The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.Haematologica. 2009 Sep;94(9):1307-11. doi: 10.3324/haematol.2009.008045.
87	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Leuk Lymphoma. 2016 Sep;57(9):1991-2013. doi: 10.3109/10428194.2016.1173212. Epub 2016 Apr 27.
88	Discovery of a first-in-class EZH2 selective degrader.Nat Chem Biol. 2020 Feb;16(2):214-222. doi: 10.1038/s41589-019-0421-4. Epub 2019 Dec 9.
89	High molecular response rate and clinical correlation in patients with follicular lymphoma treated with cyclophosphamide-vincristine-prednisone plus interferon alpha 2b.Clin Cancer Res. 2003 Jul;9(7):2497-503.
90	The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment.J Leukoc Biol. 2017 Sep;102(3):711-717. doi: 10.1189/jlb.3MR0117-033R. Epub 2017 Apr 13.
91	The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma.Blood. 2010 Mar 18;115(11):2214-9. doi: 10.1182/blood-2009-08-236265. Epub 2009 Nov 25.
92	Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.Environ Mol Mutagen. 2013 Jan;54(1):72-7. doi: 10.1002/em.21739. Epub 2012 Oct 11.
93	Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature.Onco Targets Ther. 2019 Sep 23;12:7833-7842. doi: 10.2147/OTT.S211436. eCollection 2019.
94	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.Mod Pathol. 2016 Jul;29(7):685-97. doi: 10.1038/modpathol.2016.79. Epub 2016 Apr 22.
95	Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression.Haematologica. 2008 Dec;93(12):1822-8. doi: 10.3324/haematol.13239. Epub 2008 Oct 22.
96	Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.J Clin Oncol. 2019 Dec 1;37(34):3300-3309. doi: 10.1200/JCO.18.02365. Epub 2019 Aug 28.
97	The relationship of REL proto-oncogene to pathobiology and chemoresistance in follicular and transformed follicular lymphoma.Leuk Res. 2017 Mar;54:30-38. doi: 10.1016/j.leukres.2017.01.001. Epub 2017 Jan 9.
98	Variations in chromosomes 9 and 6p21.3 with risk of non-Hodgkin lymphoma.Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):42-9. doi: 10.1158/1055-9965.EPI-10-0638. Epub 2010 Dec 10.
99	Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32).Int J Hematol. 2015 Nov;102(5):633-8. doi: 10.1007/s12185-015-1823-z. Epub 2015 Jun 27.
100	TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.Blood. 2012 Aug 23;120(8):1613-23. doi: 10.1182/blood-2011-09-382838. Epub 2012 May 29.
101	Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature.Virchows Arch. 2020 Apr;476(4):609-614. doi: 10.1007/s00428-019-02691-w. Epub 2019 Dec 5.
102	Recurrent mutations in genes involved in nuclear factor-B signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.Histopathology. 2017 Jan;70(2):174-184. doi: 10.1111/his.13015. Epub 2016 Sep 9.
103	A new death receptor 3 isoform: expression in human lymphoid cell lines and non-Hodgkin's lymphomas.Biochem Biophys Res Commun. 1998 Jan 14;242(2):376-9. doi: 10.1006/bbrc.1997.7948.
104	Detection and quantification of MBR/JH2 t(14;18) BCL-2 gene rearrangement in follicular lymphoma using a combined real-time polymerase chain reaction assay.Haematologica. 2006 Jun;91(6):858-9. Epub 2006 May 16.
105	Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.Clin Cancer Res. 2017 Nov 15;23(22):7119-7129. doi: 10.1158/1078-0432.CCR-17-1144. Epub 2017 Aug 29.
106	Divergent immunohistochemical expression of CD21 and CD23 by follicular dendritic cells with increasing grade of follicular lymphoma.World J Surg Oncol. 2019 Jul 3;17(1):115. doi: 10.1186/s12957-019-1659-8.
107	CXCR5 and ICOS expression identifies a CD8 T-cell subset with T(FH) features in Hodgkin lymphomas.Blood Adv. 2018 Aug 14;2(15):1889-1900. doi: 10.1182/bloodadvances.2018017244.
108	Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin's Lymphoma Risk and Survival.PLoS One. 2015 Oct 8;10(10):e0139329. doi: 10.1371/journal.pone.0139329. eCollection 2015.
109	Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.Mod Pathol. 2018 Feb;31(2):313-326. doi: 10.1038/modpathol.2017.134. Epub 2017 Oct 6.
110	Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction.Int J Hematol. 2020 Apr;111(4):585-590. doi: 10.1007/s12185-019-02793-w. Epub 2019 Dec 17.
111	Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1.Leukemia. 2002 Feb;16(2):276-83. doi: 10.1038/sj.leu.2402372.
112	Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement.Blood. 2012 Sep 20;120(12):2395-404. doi: 10.1182/blood-2012-05-429514. Epub 2012 Jul 31.
113	Differential usage of an Ig heavy chain variable region gene by human B-cell tumors.Blood. 1993 Jul 1;82(1):224-30.
114	A novel fusion 5'AFF3/3'BCL2 originated from a t(2;18)(q11.2;q21.33) translocation in follicular lymphoma.Oncogene. 2008 Oct 16;27(47):6187-90. doi: 10.1038/onc.2008.214. Epub 2008 Jul 14.
115	DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma.Genes Chromosomes Cancer. 2009 Sep;48(9):828-41. doi: 10.1002/gcc.20687.
116	BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma.Leuk Lymphoma. 2019 May;60(5):1283-1288. doi: 10.1080/10428194.2018.1529310. Epub 2018 Nov 27.
117	Molecular analysis of the BCL-3 locus at chromosome 17q22 in B-cell neoplasms.Blood. 1993 Sep 15;82(6):1813-9.
118	A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.Clin Cancer Res. 2008 Oct 15;14(20):6697-703. doi: 10.1158/1078-0432.CCR-08-0745.
119	Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays.Blood. 2002 Jan 1;99(1):282-9. doi: 10.1182/blood.v99.1.282.
120	Immunoglobulin diversification in B cell malignancies: internal splicing of heavy chain variable region as a by-product of somatic hypermutation.Leukemia. 2002 Apr;16(4):636-44. doi: 10.1038/sj.leu.2402405.
121	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.Am J Hematol. 2012 Sep;87(9):880-5. doi: 10.1002/ajh.23273. Epub 2012 Jun 20.
122	Cytogenetic changes in the progression of lymphoma.Leuk Lymphoma. 1998 Sep;31(1-2):1-19. doi: 10.3109/10428199809057581.
123	Follicular lymphoma frequently originates in the salivary gland.Pathol Int. 2006 Oct;56(10):576-83. doi: 10.1111/j.1440-1827.2006.02011.x.
124	Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene.Proc Natl Acad Sci U S A. 1988 Nov;85(22):8548-52. doi: 10.1073/pnas.85.22.8548.
125	Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma.Am J Pathol. 1999 Apr;154(4):1023-35. doi: 10.1016/S0002-9440(10)65355-2.
126	Follicular lymphoma-protective HLA class II variants correlate with increased HLA-DQB1 protein expression.Genes Immun. 2014 Mar;15(2):133-6. doi: 10.1038/gene.2013.64. Epub 2013 Dec 5.
127	Lamin B1 regulates somatic mutations and progression of B-cell malignancies.Leukemia. 2018 Feb;32(2):364-375. doi: 10.1038/leu.2017.255. Epub 2017 Aug 14.
128	Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas.Histopathology. 2017 Oct;71(4):648-660. doi: 10.1111/his.13279. Epub 2017 Jul 19.
129	Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation.J Clin Oncol. 2013 Jul 20;31(21):2654-61. doi: 10.1200/JCO.2012.44.2137. Epub 2013 Jun 17.
130	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.Blood. 2014 Mar 6;123(10):1487-98. doi: 10.1182/blood-2013-05-500264. Epub 2014 Jan 16.
131	Expression of the Rho-family GTPase gene RHOF in lymphocyte subsets and malignant lymphomas.Br J Haematol. 2005 May;129(4):531-3. doi: 10.1111/j.1365-2141.2005.05481.x.
132	In situ detection of activated cytotoxic cells in follicular lymphomas.Am J Pathol. 1994 Mar;144(3):492-9.
133	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7.
134	Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.Clin Cancer Res. 2017 Feb 15;23(4):954-961. doi: 10.1158/1078-0432.CCR-16-1275. Epub 2016 Aug 15.
135	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.J Clin Oncol. 2018 Mar 1;36(7):697-703. doi: 10.1200/JCO.2017.74.5083. Epub 2018 Jan 22.
136	Analysis of GNA13 Protein in Follicular Lymphoma and its Association With Poor Prognosis.Am J Surg Pathol. 2018 Nov;42(11):1466-1471. doi: 10.1097/PAS.0000000000000969.
137	KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas.Am J Clin Pathol. 2017 Nov 20;148(6):465-476. doi: 10.1093/ajcp/aqx099.
138	Protocadherin A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth.Mol Med Rep. 2016 Nov;14(5):4622-4628. doi: 10.3892/mmr.2016.5808. Epub 2016 Oct 5.
139	Identification of TRA-1-60-positive cells as a potent refractory population in follicular lymphomas.Cancer Sci. 2019 Jan;110(1):443-457. doi: 10.1111/cas.13870. Epub 2018 Dec 8.
140	Polymorphisms in DNA repair genes, hair dye use, and the risk of non-Hodgkin lymphoma.Cancer Causes Control. 2014 Oct;25(10):1261-70. doi: 10.1007/s10552-014-0423-1. Epub 2014 Sep 2.
141	Aberrant somatic hypermutations in thyroid lymphomas.Leuk Res. 2009 May;33(5):649-54. doi: 10.1016/j.leukres.2008.10.007. Epub 2008 Nov 18.
142	A new method to detect loss of heterozygosity using cohort heterozygosity comparisons.BMC Cancer. 2010 May 12;10:195. doi: 10.1186/1471-2407-10-195.
143	Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25.
144	Mutations in apoptosis genes: a pathogenetic factor for human disease.Mutat Res. 2001 Jul;488(3):211-31. doi: 10.1016/s1383-5742(01)00057-6.
145	Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas.Blood. 2008 Jan 1;111(1):351-8. doi: 10.1182/blood-2007-06-094151. Epub 2007 Sep 26.
146	Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.J Clin Invest. 2019 Mar 4;129(4):1626-1640. doi: 10.1172/JCI98288. eCollection 2019 Mar 4.
147	Bcl-B expression in human epithelial and nonepithelial malignancies.Clin Cancer Res. 2008 May 15;14(10):3011-21. doi: 10.1158/1078-0432.CCR-07-1955.
148	Follicular lymphoma (FL): Immunological tolerance theory in FL.Hum Immunol. 2017 Feb;78(2):138-145. doi: 10.1016/j.humimm.2016.09.010. Epub 2016 Sep 30.
149	Mutations of the BIK gene in human peripheral B-cell lymphomas.Genes Chromosomes Cancer. 2003 Sep;38(1):91-6. doi: 10.1002/gcc.10245.
150	Follicular lymphoma: are we ready for a risk-adapted approach?.Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):358-364. doi: 10.1182/asheducation-2017.1.358.
151	Primary cilia are increased in number and demonstrate structural abnormalities in human cancer.J Clin Pathol. 2017 Jul;70(7):571-574. doi: 10.1136/jclinpath-2016-204103. Epub 2016 Nov 21.
152	DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma.Haematologica. 2006 Sep;91(9):1252-6.
153	DOCK2 regulates cell proliferation through Rac and ERK activation in B cell lymphoma.Biochem Biophys Res Commun. 2010 Apr 23;395(1):111-5. doi: 10.1016/j.bbrc.2010.03.148. Epub 2010 Mar 27.
154	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.Nat Genet. 2014 Feb;46(2):176-181. doi: 10.1038/ng.2856. Epub 2013 Dec 22.
155	Expression of far upstream element binding protein1 in Bcell nonHodgkin lymphoma is correlated with tumor growth and celladhesion mediated drug resistance.Mol Med Rep. 2016 Oct;14(4):3759-68. doi: 10.3892/mmr.2016.5718. Epub 2016 Sep 6.
156	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32.Nat Genet. 2010 Aug;42(8):661-4. doi: 10.1038/ng.626. Epub 2010 Jul 18.
157	Multi-locus HLA class I and II allele and haplotype associations with follicular lymphoma.Tissue Antigens. 2012 Apr;79(4):279-86. doi: 10.1111/j.1399-0039.2012.01845.x. Epub 2012 Feb 2.
158	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.Blood. 2017 Jan 26;129(4):473-483. doi: 10.1182/blood-2016-07-729954. Epub 2016 Nov 14.
159	The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.Mol Carcinog. 2019 Jun;58(6):944-956. doi: 10.1002/mc.22983. Epub 2019 Feb 27.
160	Pathogenesis of follicular lymphoma.Best Pract Res Clin Haematol. 2018 Mar;31(1):2-14. doi: 10.1016/j.beha.2017.10.006. Epub 2017 Nov 1.
161	Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas.Oncotarget. 2018 Jan 5;9(8):7928-7941. doi: 10.18632/oncotarget.23974. eCollection 2018 Jan 30.
162	Comprehensive cytogenetic analysis including multicolor spectral karyotyping and interphase fluorescence in situ hybridization in lymphoma diagnosis. a summary of 154 cases.Cancer Genet Cytogenet. 2003 May;143(1):73-9. doi: 10.1016/s0165-4608(02)00843-9.
163	Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.Am J Surg Pathol. 2018 Mar;42(3):342-350. doi: 10.1097/PAS.0000000000001015.
164	Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.Hum Pathol. 2007 Dec;38(12):1849-57. doi: 10.1016/j.humpath.2007.05.009. Epub 2007 Sep 27.
165	High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.Leuk Lymphoma. 2013 Aug;54(8):1652-7. doi: 10.3109/10428194.2012.753445. Epub 2012 Dec 27.
166	Aberrant expression of napsin A in a subset of malignant lymphomas.Histol Histopathol. 2016 Feb;31(2):213-21. doi: 10.14670/HH-11-669. Epub 2015 Sep 24.
167	NKL homeobox gene activities in B-cell development and lymphomas.PLoS One. 2018 Oct 11;13(10):e0205537. doi: 10.1371/journal.pone.0205537. eCollection 2018.
168	PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.Oncotarget. 2016 Sep 13;7(37):59158-59172. doi: 10.18632/oncotarget.10993.
169	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.PLoS One. 2019 Feb 25;14(2):e0212813. doi: 10.1371/journal.pone.0212813. eCollection 2019.
170	Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma.Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):734-742. doi: 10.1016/j.clml.2017.06.034. Epub 2017 Jun 30.
171	Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA.Future Oncol. 2018 Oct;14(25):2627-2642. doi: 10.2217/fon-2018-0267. Epub 2018 Jun 18.
172	MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.Methods Mol Biol. 2019;1956:199-228. doi: 10.1007/978-1-4939-9151-8_9.
173	Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma.Blood. 1995 Oct 15;86(8):3072-82.
174	Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma.Leuk Res. 2017 Jun;57:89-96. doi: 10.1016/j.leukres.2017.02.012. Epub 2017 Mar 9.
175	Splicing factor SRP20 is a novel partner of BCL6 in a t(3;6)(q27;p21) translocation in transformed follicular lymphoma.Genes Chromosomes Cancer. 2001 Nov;32(3):281-4. doi: 10.1002/gcc.1191.
176	Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma.Hum Pathol. 1995 Nov;26(11):1227-32. doi: 10.1016/0046-8177(95)90198-1.
177	Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract.Appl Immunohistochem Mol Morphol. 2013 May;21(3):200-4. doi: 10.1097/PAI.0b013e31826399aa.
178	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.Blood. 2016 Dec 8;128(23):2666-2670. doi: 10.1182/blood-2016-03-704528. Epub 2016 Sep 26.
179	Impact of age on clinical risk scores in follicular lymphoma.Blood Adv. 2019 Apr 9;3(7):1033-1038. doi: 10.1182/bloodadvances.2019032136.